Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CorMedix Inc CRMD

Healthcare
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections... see more

Recent & Breaking News (NDAQ:CRMD)

CorMedix Inc. to Present at the Anti-Infectives Rx Conference

Accesswire September 12, 2017

CorMedix Inc. Presents Data Demonstrating Antimicrobial Activity of Taurolidine Against Potentially Deadly Fungal Pathogen Candida auris

Accesswire September 7, 2017

CorMedix Inc. to Present at 2017 Rodman & Renshaw 19th Annual Global Investment Conference

Accesswire September 5, 2017

CorMedix Inc. Announces a Change to its Senior Leadership

Accesswire August 25, 2017

CorMedix, Inc. Awarded NIH Grant to Develop Advanced Antimicrobial Hydrogels for the Treatment and Prevention of Potentially Life-Threatening Infections in Severe Burns

Accesswire August 17, 2017

CorMedix Inc. Reports Second Quarter Financial Results and Provides Business Update

Accesswire August 9, 2017

Investor Network: CorMedix Inc. to Host Earnings Call

Accesswire August 9, 2017

CorMedix Inc. Appoints Gary Gelbfish, M.D., to Board of Directors

Accesswire August 7, 2017

CorMedix Inc. to Report Second Quarter 2017 Financial Results and Provide Business Update

Accesswire August 4, 2017

CorMedix Inc. Provides Update on Neutrolin(R) Ongoing Phase 3 Clinical Trial Following Favorable FDA Correspondence

Accesswire August 2, 2017

CorMedix Inc. Provides Comprehensive Pipeline Update During Research and Development Day

Accesswire July 12, 2017

CorMedix Inc. Appoints Mehmood Khan, M.D. and Steven Lefkowitz to its Board of Directors

Accesswire June 26, 2017

CorMedix Inc. to Showcase Its Taurolidine-Based Development Pipeline at Research and Development Day

Accesswire June 14, 2017

CorMedix Inc. Announces Changes to Board of Directors

Accesswire June 12, 2017

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of First American Financial Corporation

Business Wire May 26, 2017

CorMedix Inc. Reports First Quarter Financial Results and Provides Business Update

Accesswire May 10, 2017

CorMedix Inc. Demonstrates Sensitivity of Emerging Global Health Threat Candida auris to Taurolidine

Accesswire May 9, 2017

CorMedix Inc. to Report First Quarter 2017 Financial Results and Provide Business Update

Accesswire May 5, 2017

CorMedix Inc. Announces Closing of Public Offering of Common Stock and Warrants and Underwriter's Exercise in Full of Over-Allotment Option

Accesswire May 3, 2017

CorMedix Inc. Increases Previously Announced Public Offering to $12.1 Million

Accesswire April 28, 2017